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Abstract
Predicting prognosis in the patient with newly diagnosed
rheumatoid arthritis is of key importance so that high-cost therapies
can be tailored to the needs of the individual. In a recent issue of
Arthritis Research and Therapy, the prognostic significance of MRI
changes at the forefoot has been studied. While progression to
radiographic erosion occurred rarely in this group of patients
exposed to potent disease-suppressing therapies, including TNF
inhibitors, MRI bone edema, representing osteitis, has been further
implicated as a forerunner to bone erosion. Early MRI scans of the
forefoot were helpful in defining those with the potential to
progress as well as those in a good prognosis category.
In a recent issue of Arthritis Research and Therapy, Mund-
wiler and colleagues [1] have investigated the prognostic
significance of magnetic resonance imaging (MRI) changes
at the forefoot in patients with early rheumatoid arthritis (RA).
While there is already an extensive literature investigating the
hand and wrist in this context [2-4], much less information
exists regarding the forefoot, where radiographic (XR)
changes appear early [5]. A previous study has indicated that
MRI synovitis, bone edema and erosion can be detected
within weeks of the onset of symptoms [6], and of these
features, bone edema has repeatedly been shown to be the
most important predictor of future erosions at the wrist [2-4].
It is therefore timely to examine the importance of MRI
scanning of the feet, using a longitudinal study design to
define early prognostic markers.
Mundwiler and colleagues set out primarily to determine the
sensitivity, specificity, and predictive value of MRI erosions at
individual metatarsophalangeal (MTP) joints for the develop-
ment of new XR erosions after 6, 12, and 24 months. Secon-
dary objectives were to determine the prognostic significance
of MRI synovitis and bone edema and to examine the persis-
tence of those findings over time. Their cohort of patients
differed from those studied by McQueen and colleagues [2]
in that almost half (46%) had received anti-TNF therapy and
were, therefore, representative of a modern RA population
receiving aggressive management in the biologics era.
Comparing their results with those of previous similar studies
is a most interesting exercise. At first glance they might seem
to be contradictory as the presence of an MRI erosion at
baseline had a low positive predictive value for the later
development of an XR erosion at that site (0.17 at
24 months). However, the negative predictive value was
extremely high at 0.99, virtually guaranteeing that, in its
absence, an XR erosion would not develop. This is a very
similar result to that described previously in the New Zealand
cohort where the negative predictive value for MRI erosions
predicting XR erosions after 1 year was 0.91 [7]. The reason
why the positive predictive values were so low in the
Mundwiler cohort was that this group hardly eroded at all.
Only five new XR erosions actually formed for the entire
group over the 24-month period, presumably reflecting the
impact of modern disease-suppressing therapies, including
anti-TNF agents.
MRI bone edema was a better predictor of erosions, with a
positive predictive value of 0.5 at 24 months, and this
supports the findings of previous studies at the hand and
wrist [2-4]. At the individual joint level, having bone edema
dramatically increased the chance of eroding, with an odds
ratio of 68.0 at 12 months, although caveats remain regard-
ing confidence intervals due to small numbers. These results
also suggest that this risk is reversible (progression to XR
erosion did not occur in 50% of cases), pointing to the
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influence of therapeutic intervention. When the antecedents
to XR erosions were examined, MRI erosions were detected
in 75% of cases but the other 25% of scans were also
abnormal, revealing bone defects. This class of lesion does
not fulfill current criteria for erosion using the rheumatoid
arthritis MRI scoring system (RAMRIS), having no cortical
break [8]. An early version of this scoring system did include
bone defects but the category was later dropped because of
poor scoring reliability [9]. Nevertheless, these results
suggest that an area of well-defined signal change in the
subchondral bone, suggesting trabecular loss, could be
significant. A recent study examining the histopathology of
bone excised from RA patients at joint replacement revealed
high densities of osteoclasts and RANKL (receptor activator
for nuclear factor κB ligand) staining adjacent to subchondral
bony trabeculae in regions where bone edema was present
on preoperative MRI scans [10]. These findings suggest a
mechanism for bone loss without breaching the cortical plate,
where bone edema might be followed by a subchondral bone
defect, which could in turn precede the development of
erosion (Figure 1).
What do the findings of Mundwiler and colleagues tell us
about the role of synovitis as a pre-erosive lesion? Synovitis
was common, being observed in 74% of cases. It was
detected as an isolated finding in 52 MTP joints and in these
it resolved in two-thirds of cases without the appearance of
other lesions. In one-quarter of cases, synovitis persisted
without other lesions appearing, and in only 6% of MTPs,
where it was an initial isolated finding, did bony lesions
develop. This would tend to imply that while synovitis is a very
common finding in RA, it is not in itself pre-erosive. Its strong
association with bone edema (which was accompanied here
by synovitis in all but one instance) suggests that the lesions
are often linked but this is not invariable. In those patients
with pure synovitis and without bone edema, the prognosis
may be more favourable. Further studies to follow the
progress of these ‘good prognosis’ patients are warranted as
the ‘hit hard and early’ treatment philosophy may not serve in
their best interests. Conversely, the appearance of definite
bone edema needs to serve as a red flag for rheumatologists
and active management with powerful anti-erosive
medications such as TNF inhibitors should be considered
urgently for these patients.
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Figure 1
A model of rheumatoid arthritis, implicating subchondral osteitis and RANKL-mediated osteoclastogenesis in the development of bone erosion.
(a) Resting subchondral trabecular bone. (b) Osteitis (bone edema on MRI) characterised by infiltrates of macrophages, lymphocytes and plasma
cells adjacent to osteoclasts. RANKL staining abundant adjacent to trabeculae [10]. (c) Activated osteoclasts resorb trabecular bone leading to
intra-osseous erosion formation (subchondral bone defects on MRI). (d) Cortical bone erosion develops. MRI = magnetic resonance imaging;
RANK, receptor activator for nuclear factor κB; RANKL, RANK ligand.References
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